Geminor M2 Forte Tablet PR
By Geminor M
Rx
15 Tablet PR in a Strip

Composition
Glimepiride(2mg) + Metformin(1000mg)

Manufacturer - Macleods Pharmaceuticals Pvt Ltd
Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai - 400059, INDIA.

Expires on or after
February, 2026

liver
When taking Geminor M2 Forte Tablet PR, it's crucial to be cautious if you have liver disease. Your doctor may need to adjust the dosage accordingly. Typically, in individuals with mild to moderate liver disease, Geminor M2 Forte Tablet PR is initiated at a low dose. However, it is not advisable for those with severe liver disease to use this medication without proper guidance from a healthcare provider. Always consult your doctor regarding the use of Geminor M2 Forte Tablet PR if you have any liver-related concerns.

kidney
Geminor M2 Forte Tablet PR should be used with caution in patients with kidney disease. Dose adjustment may be required, and it is not recommended for severe kidney disease. Regular kidney function tests are advised during use. Consult your doctor for proper guidance before using Geminor M2 Forte Tablet PR.

alcohol
It is not safe to drink alcohol while taking Geminor M2 Forte Tablet PR. Drinking alcohol with this medication can be harmful.

driving
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.

pregnancy
Geminor M2 Forte Tablet PR might not be safe during pregnancy, with animal studies indicating potential harm to the developing baby. Your doctor will assess the risks and benefits before recommending this medication. It is crucial to consult your doctor regarding its use during pregnancy.

breastfeeding
Caution is advised when breastfeeding while using Geminor M2 Forte Tablet PR as it is considered unsafe and may pose risks of toxicity to the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI DIABETIC |
Action Class | - |
₹207.9
Inclusive of all taxes
Content verified by

Dr. Upasana Bhatia
MBBS - General Medicine
Last update on 01-Oct-2024